Drug Trial Radar · NCT06770933
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 11, 2025
Primary completion
Jul 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Vantage Biosciences LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Vantage Biosciences Australia Pty Ltd
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Type (NPDR). The primary objective of the study is to evaluate the efficacy of daily oral doses of VX-01 versus placebo following 52 weeks of treatment.
Conditions
- Diabetic Retinopathy
- NPDR - Non Proliferative Diabetic Retinopathy
Interventions
VX-01Drug
There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
PlaceboDrug
Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy of oral doses of VX-01 in subjects compared to placebo following 1 year of treatment.Time frame: From enrollment to the end of treatment at week 52
Locations
27 sites in 5 countries. Site status is shown where the registry gives one.
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Stanford Byers Eye Institute
Palo Alto, California
California Retina Consultants- Santa Barbara
Santa Barbara, California
Florida Retina Institute - Jacksonville Southside
Jacksonville, Florida
Southeast Retina Center
Augusta, Georgia
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Sterling Vision, PC
Eugene, Oregon
Erie Retina Research
Erie, Pennsylvania
Piedmont Eye Center
Lynchburg, Virginia
Eye Clinic Albury Wodonga
Albury, New South Wales, Australia
Retina And Eye Consultants Hurstville
Hurstville, New South Wales, Australia
Marsden Eye Specialists
Parramatta, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
Sydney Retina Clinic
Sydney, New South Wales, Australia
Sydney West Retina
Westmead, New South Wales, Australia
University of the Sunshine Coast Clinical Trials (Birtinya)
Birtinya, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Prince of Wales Hospital The Chinese University of Hong Kong
Shatin, Hong Kong
HKU Eye Centre
Wong Chuk Hang, Hong Kong
Hospital Selayang
Selayang Baru Utara, Malaysia
University Malaya Medical Centre
Petaling Jaya, Kuala Lumpur Federal Territory of Kuala Lumpur, Malaysia
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia
Hospital Shah Alam
Shah Alam, Selangor, Malaysia
Hospital Al-sultan Abdullah Uitm
Sungai Buloh, Selangor, Malaysia
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.